Participate in Research
Anyone who is considering participating in a research study or clinical trial is encouraged to speak with their health care provider(s) about the benefits and risks.
The information provided on this website is intended to help you identify studies and trials that may be relevant to you. Each listing includes eligibility parameters based on age and time since diagnosis (when applicable), but additional eligibility criteria may exist; please review the Clinical Trials Registry link or use the Study Website or Study Contact links for more information about eligibility.
Please note that while ClinicalTrials.gov is only available in English, study teams will make every possible attempt to interact in multiple languages unless otherwise stated. This may include having French and English materials available or employing translators.
Location identifies where a study is being conducted. Some studies may provide travel subsidies for out-of-town or out-of-province participants. Use the Study Website or Study Contact links to inquire directly with the research team about the possibility of travelling to participate in the study. Other studies may be conducted virtually, for example if the intervention is based on access to a digital platform.
Clinical Trial Phases are given where appropriate: Phase 1 is usually in a small number of participants (~20-100) to test that the intervention has the desired effect and assess side effects, Phase 2 (~100-300 participants) assesses the efficacy of the intervention on T1D outcomes and examines the best dosage levels, frequency, etc. Phase 3 is greater proof of efficacy (~300-1000 participants) compared to any existing treatments or existing ‘standard of care’.
*Page last updated September 2023*
Pediatric (under 18 years)
Eligibility: Everyone (≤13yo parental registry, ≥14yo individual registry).
Project Summary: This registry is for anyone in Canada living with T1D. The registry is considered research since it collects information from registrants about demographic and diabetes management information. The registry benefits participants by creating a more accurate picture of T1D in Canada. It also provides valuable support with webinars, videos, and communications regarding all things T1D.
PI(s): Dr. Remi Rhabasa-Lhoret, Institut de Recherches Cliniques de Montréal
Adults (18 years or older)
JDRF-funded studies that are active but not recruiting
Location(s): Toronto, ON and London, ON
Eligibility: aged 12-18 years with T1D for at least 1-year
Project Summary: ATTEMPT is a 22-week clinical trial that aims to determine the safety and effectiveness of an SGLT2 inhibitor called dapagliflozin (currently used for T2D) on managing blood glucose and preventing kidney complications in adolescents with T1D.
Trial Status: Ongoing – participant recruitment is completed. JDRF will update as results become available.
Drug Information: Dapagliflozin vs placebo (sugar)
PI(s): Dr. Farid Mahmud, The Hospital for Sick Children
Find Out About T1D Trials in Canada and Beyond
Whether you want to learn about clinical trials, consider participating, or support a clinical trial – we want help you find the information you need. Try our T1D trial finder tool.